FASN and hepatocellular carcinoma: In preclinical HCC models, pharmacological inhibition of FASN restores T-cell effector function, increases MHC I expression, enhances tumor antigen presentation, and cooperates with PD-1/PD-L1 blockade (details see Table 3) [173].